CPPs have been assessed for their potential to enhance PMO uptake for the treatment of a spectrum of conditions, including Duchenne muscular dystrophy (DMD) [119], myotonic dystrophy type I [120], Huntington’s disease, amyotrophic lateral sclerosis [121], and SMA [5]. The gene discussed is SMN1; the disease is Duchenne muscular dystrophy.